Please ensure Javascript is enabled for purposes of website accessibility
Home > Support > Literature Updates

Tumor-infiltrating plasma cell targets as a source for immunotherapies

Cancer Cell (27 July 2026)

Tumor-infiltrating plasma cells are key responders to immunotherapy. In this issue of Cancer Cell, Meyerhoff et al. show that plasma cells from lung lesions of anti-PD-1-treated patients target citrullinated proteins. Engineering CAR T cells with these plasma cells scFv reveals anti-tumor specificity without adverse effects, identifying therapeutic opportunities.

Related products

Catalog No. Product Name Description Target
HX959021 Recombinant Human CD269/TNFRSF17/BCMA Protein Recombinant Human CD269/TNFRSF17/BCMA Protein, C-Fc (HX959021) expressed in Mammalian Cells, spanning Leu2-Ala54. Purity: >90% by SDS-PAGE. Highlights ●Fc Fusion — Enhanced stability with Protein A/G purification compatibility. ●Mammalian Expression — Proper folding and native glycosylation. ●High Purity — >90% purity verified by SDS-PAGE.